A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
NCT03121768 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 761
Last updated 2017-05-16
Summary
A prospective observational study to re-establish a new prognostic model for predicting the outcome in patients with non-muscle invasive bladder cancer (NMIBC) using the current recommendation regimen for intermediate and high risk groups and including all potential and highly prognostic factors.
Conditions
- Oncology
- Bladder Cancer
- Superficial Bladder Cancer
- Recurrence
- Progression
- BCG
Sponsors & Collaborators
-
Mansoura University
lead OTHER
Principal Investigators
-
Ahmed Mosbah, MD · Urology and Nephrology Center
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-05-15
- Primary Completion
- 2019-12-01
- Completion
- 2022-04-01
Countries
- Egypt
More Related Trials
-
Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer
NCT02214602 ·Status: COMPLETED ·Phase: PHASE4
-
Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer
NCT05946369 ·Status: COMPLETED
-
Sensitivity of Multiparametric MRI in Differentiation Between Muscle Invasive and Non-muscle Invasive Urinary Bladder Cancer
NCT05324033 ·Status: COMPLETED
-
Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study
NCT05626101 ·Status: RECRUITING ·Phase: NA
-
Diagnostic Performance and Predictive Capacity of Immediate Urine Cytology After Transurethral Resection of Non-Muscle Invasive Bladder Cancer; A Prospective Study
NCT04194112 ·Status: COMPLETED ·Phase: NA
-
Optimal Adjuvant Intravesical Therapy for Intermediate Risk Non Muscle Invasive Bladder Cancer: A Randomized Controlled Trial
NCT05146635 ·Status: UNKNOWN ·Phase: NA
-
Microscopic-spectroscopic Examination for Urothelial Tissue Characterization
NCT04310813 ·Status: COMPLETED
-
Evaluation of PD-L1 Expression and Immune Infiltration in High-risk Non Muscle Invasive Bladder Cancer
NCT04726735 ·Status: COMPLETED
-
Basal Like Bladder Cancer : Signature and Therapeutic
NCT02648100 ·Status: UNKNOWN
-
A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder
NCT03519256 ·Status: TERMINATED ·Phase: PHASE2
-
Follow-Up of Bladder Cancer Patients From the New England Study of Environment and Health
NCT00776178 ·Status: COMPLETED
-
Outcome of Treating Bladder Cancer in Sohag University Hospital
NCT05082818 ·Status: COMPLETED
-
A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC
NCT06971614 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
NCT04172675 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of 9MW2821 in the Treatment of High-risk Non-muscle-invasive Bladder Cancer (NMIBC)
NCT06551233 ·Status: RECRUITING ·Phase: PHASE1
-
In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both?
NCT03174912 ·Status: COMPLETED ·Phase: PHASE4
-
Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer
NCT02808143 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
NCT03661320 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
NCT06138561 ·Status: RECRUITING
-
The Potential Role Of MicroRNA-155 And Telomerase Reverse Transcriptase In Diagnosis Of Non-Muscle Invasive Bladder Cancer And Their Pathological Correlation
NCT03591367 ·Status: COMPLETED ·Phase: NA
-
Skipping BCG for T1a Urinary Bladder Tumor.
NCT04298073 ·Status: UNKNOWN
-
Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)
NCT05825950 ·Status: RECRUITING
-
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
NCT02138734 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.
NCT07064863 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
NCT06211764 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3